| abstract |
The present invention relates to compounds that inhibit farnesyl protein transferase and ras protein farnesylation and are useful as anticancer agents because of these properties. In addition, the compounds are useful for the treatment of diseases associated with signal transduction pathways that operate through las in addition to cancer and diseases involving proteins that are post-translationally modified by the enzyme farnesyl protein transferase in addition to las. In addition, these compounds may act as inhibitors of other prenyl transferases and thus may be effective in the treatment of diseases associated with other prenyl variations of the protein. |